Speeding OTC and behind-the-counter switches mulled to boost adherence

Share this article:
Zyrtec OTC
Zyrtec OTC
The FDA says it is looking for change in the OTC market that could help move more drugs from prescription to over-the-counter status.

The agency said in the February 23 Federal Register that it is looking to remove some of the barriers that may come between a patient and compliance and is holding a hearing March 22 and 23 to get feedback.

“The requirement to obtain a prescription for appropriate medication (and to make one or more visits to a practitioner) may contribute to under-treatment of certain common medical conditions,” the agency said in a in the Federal Register. The agency says it is looking for information about the technology the industry has on tap that could help patients get greater access without increasing possible risk.

The FDA said these options may include an over-the-counter-but-through-the-pharmacist approach in which a patient doesn't require a prescription, but does need to consult the pharmacist “to ensure appropriate nonprescription use.”

The agency said it is also open to allowing FDA-approved diagnostics to match patients to treatment options, but notes that even the most rigorous pharmacy tutorials or tech has limits and is looking to pinpoint the types of drugs that could be safely used without a prescription.

Success among the prescription-to-OTC categories has been varied. Merck has failed several times to get OTC approval for its statin Mevacor, because surveys shows patients would take the drug even if they didn't need it, and analysts have been temperate in their assessment of an OTC version of Pfizer's Lipitor.

The allergy category has done fairly well, with Sanofi's Allegra (fexofenadine) getting OTC approval in 2011. McNeil's Zyrtec (cetirizine) made the switch in 2008, and Merck's Claritin (loratadine) was put in consumer's prescription-free reach in 2002.
Share this article:

Email Newsletters

More in News

FDA kind of OKs Lilly/BI's Lantus look-alike

FDA kind of OKs Lilly/BI's Lantus look-alike

Sanofi's patent lawsuit triggered the tentative approval of the Lilly-BI Lantus competitor.

GSK relaunches COPD.com

GSK relaunches COPD.com

The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.

Six things for pharma marketers to know: Tuesday, August 19

Six things for pharma marketers to know: Tuesday, ...

Lilly/BI receives tentative approval for insulin biosimilar; Ebola death rate hits new high; LaMattina sounds off on Pfizer's oncology efforts; art therapy becoming the norm in hospitals.